Drug intelligence / Profile preview

Cizdol-N

Development stage: Phase 4
Lead developer: Maan Pharmaceuticals
Modality: Small Molecules
Administration: Sublingual

Overview

Cizdol-N is a combination sublingual tablet manufactured by Maan Pharmaceuticals, containing buprenorphine and naloxone. It is indicated for the treatment of opioid dependence and de-addiction as part of medication-assisted treatment (MAT). Buprenorphine acts as a partial agonist at the mu-opioid receptor, which helps alleviate withdrawal symptoms and cravings without producing the intense euphoria associated with full opioid agonists. Naloxone, an opioid receptor antagonist, is included to deter misuse; it remains inactive when taken sublingually as directed but blocks opioid effects if the tablet is crushed and injected.

Brand names: Cizdol-N
Other names: Buprenorphine and Naloxone Sublingual Tablets I.P.Buprenorphine/Naloxone combination

Targets

DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on Cizdol-N.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cizdol-N.